Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine

References

• Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010; 28:4895 - 902; http://dx.doi.org/10.1016/j.vaccine.2010.05.031; PMID: 20553769
   PubMed Web of Science ®Google Scholar
• Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733 - 44; http://dx.doi.org/10.1093/infdis/jir641; PMID: 22315336
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740 - 5; http://dx.doi.org/10.1016/j.vaccine.2009.12.014; PMID: 20034605
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Loeb M, Coleman BL, et al. Compatibility of AS03-adjuvanted A/H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine In press
   Google Scholar
• Rubinstein E, Predy G, Sauvé L, Hammond GW, Aoki F, Sikora C, et al. The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. CMAJ 2011; 183:E1033 - 7; http://dx.doi.org/10.1503/cmaj.110196; PMID: 21788422
   PubMed Web of Science ®Google Scholar
• Canadian community health survey: H1N1 vaccinations. Ottawa (ON): Statistics Canada; 2010. Available: www.statcan.gc.ca/daily-quotidien/100719/dq100719b-eng.htm (accessed 2011 Sept 12).
   Google Scholar
• Beyer WEP, Nauta JJP, Palache AM, Giezeman KM, Osterhaus ADME. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 2011; 29:5785 - 92; http://dx.doi.org/10.1016/j.vaccine.2011.05.040; PMID: 21624411
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Available: www.who.int/influenza/vaccines/recommendations/recommendation2010_11north/en/index/html (accessed 2011 Sept 12).
   Google Scholar
• Scheifele DW, Ochnio JJ, Halperin SA. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. Pediatr Infect Dis J 2009; 28:985 - 9; http://dx.doi.org/10.1097/INF.0b013e3181a9cc2a; PMID: 19755930
   PubMed Web of Science ®Google Scholar
• Rowe J, Yerkovich ST, Richmond P, Suriyaarachchi D, Fisher E, Feddema L, et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun 2005; 73:8130 - 5; http://dx.doi.org/10.1128/IAI.73.12.8130-8135.2005; PMID: 16299307
   PubMed Web of Science ®Google Scholar
• Levine L, Edsall G. Tetanus toxoid: what determines reaction proneness?. J Infect Dis 1981; 144:376; http://dx.doi.org/10.1093/infdis/144.4.376; PMID: 7288216
   PubMed Web of Science ®Google Scholar
• Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011; 1:e000016; http://dx.doi.org/10.1136/bmjopen-2010-000016; PMID: 22021725
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Marty K, LaJeunesse C, Fan SY, Bjornson G, Langley JM, et al. Strategies for successful rapid trials of influenza vaccine. Clin Trials 2011; 8:699 - 704; http://dx.doi.org/10.1177/1740774511419868; PMID: 21900340
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Duval B, Russell ML, Warrington R, DeSerres G, Skowronski DM, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis 2003; 36:850 - 7; http://dx.doi.org/10.1086/368189; PMID: 12652385
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010; 10:71; http://dx.doi.org/10.1186/1471-2334-10-71; PMID: 20236548
   PubMed Web of Science ®Google Scholar
• Walker WT, de Whalley P, Andrews N, Oeser C, Casey M, Michaelis L, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin Infect Dis 2012; 54:661 - 9; http://dx.doi.org/10.1093/cid/cir905; PMID: 22267719
   PubMed Web of Science ®Google Scholar
• Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 2011; 30:35 - 41; http://dx.doi.org/10.1016/j.vaccine.2011.10.062; PMID: 22063386
   PubMed Web of Science ®Google Scholar
• Langley JM, Scheifele DW, Quach C, Vanderkooi O, Ward B, McNeil S, et al. Safety and immunogenicity of 2010-2011 H1N1 2009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012; 23:3389 - 94; http://dx.doi.org/10.1016/j.vaccine.2012.03.046
   Web of Science ®Google Scholar
• De Serres G, Grenier JL, Toth E, Ménard S, Roussel R, Tremblay M, et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003; 21:2354 - 61; http://dx.doi.org/10.1016/S0264-410X(03)00094-X; PMID: 12744866
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Strauss B, De Serres G, MacDonald D, Marion SA, Naus M, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event?. Clin Infect Dis 2003; 36:705 - 13; http://dx.doi.org/10.1086/367667; PMID: 12627354
   PubMed Web of Science ®Google Scholar
• De Serres G, Toth E, Ménard S, Grenier JL, Roussel R, Tremblay M, et al. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons. Vaccine 2005; 23:3726 - 32; http://dx.doi.org/10.1016/j.vaccine.2005.01.154; PMID: 15882534
   PubMed Web of Science ®Google Scholar
• Boulianne N, De Serres G, Duval B, Shadmani R, Rochette L. Clinical manifestations and incidence of oculo-respiratory syndrome following influenza vaccination--Quebec, 2000. Can Commun Dis Rep 2001; 27:85 - 90; PMID: 11396047
   PubMedGoogle Scholar
• Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, West DJ, Anthrax Vaccine Export Committee. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 2002; 11:189 - 202; http://dx.doi.org/10.1002/pds.712; PMID: 12051118
   PubMed Web of Science ®Google Scholar
• Huijskens E, Rossen J, Mulder P, van Beek R, van Vugt H, Verbakel J, et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011; 18:1401 - 5; http://dx.doi.org/10.1128/CVI.05046-11; PMID: 21795459
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Manual on Animal Influenza Diagnosis and Surveillance, 2002. Available at: www.who.int/vaccine research/diseases/influenza/WHO manual on animal-diagnosis and surveillance 2002 5.pdf [accessed February 15, 2012]
   Google Scholar
• Wood JM, Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol (Basel) 2003; 115:9 - 16; PMID: 15088770
   PubMedGoogle Scholar